New Enterprise Associates, Inc. (NEA)
New Enterprise Associates, Inc. (NEA) is a global venture capital firm focused on helping entrepreneurs build transformational businesses across multiple stages, sectors and geographies. With nearly $17 billion in cumulative committed capital since the firm’s founding in 1977, NEA invests in technology and healthcare companies at all stages in a company’s lifecycle, from seed stage through IPO. The firm’s long track record of successful investing includes more than 200 portfolio company IPOs and more than 320 acquisitions since its founding in 1977. In the U.S., NEA has offices in Menlo Park, CA; Boston, MA; New York, NY; Chicago, IL; and the Washington, D.C. metropolitan area. In addition, New Enterprise Associates (India) Pvt. Ltd. has offices in Bangalore and Mumbai, India and New Enterprise Associates (Beijing), Ltd. has offices in Beijing and Shanghai, China.
The Novartis Venture Fund (NVF)
The Novartis Venture Fund (NVF) manages over $1 billion in committed capital and more than 45 portfolio companies. NVF invests in companies with the potential to change a core therapeutic field or explore new business areas that will be critical to patient care. Our primary interest is in the development of novel therapeutics and platforms as well as medical devices and diagnostics. NVF is an independent and financially driven corporate venture fund with offices in Basel, Switzerland and Cambridge, MA.
Clarus Ventures is a global investment firm dedicated to life sciences. Founded in 2005 by a team of accomplished investment and operating professionals, we approach healthcare investing with a passion for novel ideas and the discipline to generate attractive and predictable returns. Clarus manages $1.2 billion of assets across two funds. Through multiple platforms we have invested in over 50 private and public companies in the biotechnology, medical device, and diagnostic spaces. In every investment we employ a hands-on philosophy and adhere to our investment principals which are founded on our core competencies of deep development and clinical experience, regulatory knowledge, and the ability to adapt to an ever changing investment landscape. We strive to generate outstanding returns for our investors and thrive on discovering and developing innovative products that improve people’s lives.
Satter Investment Management (SIM)
Muneer A. Satter manages Satter Investment Management (SIM), a private investment firm and family office. He also manages the Satter Foundation, a private family foundation. SIM has significant investments in several life sciences and medical technology companies. Mr. Satter is Co-Chairman and Lead Director of Vital Therapies, a publicly-traded biotech company that has created an artificial liver for patients suffering from acute liver failure. He is Chairman of Akebia Therapeutics, a publicly-traded biotech company focused on the treatment of anemia. He is Co-Chairman of Aerpio Therapeutics, a biotech company with a TIE-2 activator for diabetic macular edema and vascular leaks. He is Chairman and Co-Founder of Restorsea, a company which holds exclusive rights to a unique enzyme for an anti-aging cream. He is Co-Chairman of Linq3, a unique secure payment platform for lottery transactions. Mr. Satter is a retired partner at Goldman Sachs, where he was a partner of the firm for sixteen years. He spent his career in the Merchant Banking Division which manages the firm’s private investments.